REGEN BIOLOGICS INC 4
4 · REGEN BIOLOGICS INC · Filed Apr 10, 2008
Insider Transaction Report
Form 4
Umidi Brion
SR. VICE PRESIDENT & CFO
Transactions
- Award
STOCK OPTION (RIGHT TO BUY)
2008-04-05+16,650→ 16,650 totalExercise: $16.00Exp: 2018-04-05→ Series E Convertible Preferred Stock (16,650 underlying)
Footnotes (4)
- [F1]EXERCISE PRICE IS $0.16 PER SHARE OF COMMON STOCK IF OPTION IS EXERCISED AFTER MANDATORY CONVERSION OF SERIES E STOCK.
- [F2]EQUAL TO 1,665,000 SHARES OF COMMON STOCK AFTER MANDATORY CONVERSION OF THE SERIES E STOCK
- [F3]THE OPTION VESTS RATABLY ON A DAILY BASIS OVER FOUR YEARS FROM THE DATE OF FDA CLEARANCE OF THE COLLAGEN SCAFFOLD 510(K) APPLICATION.
- [F4]EACH SHARE OF SERIES E STOCK IS MANDATORILY CONVERTIBLE INTO 100 SHARES OF REGEN'S COMMON STOCK AT SUCH TIME AS (i) THE COMPANY'S CERTIFICATE OF INCORPORATION IS AMENDED TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK OR (ii) UPON THE EFFECTIVENESS OF A REVERSE STOCK SPLIT OF THE COMMON STOCK, SUCH THAT THERE ARE A SUFFICIENT NUMBER OF SHARES OF COMMON STOCK TO EFFECT THE CONVERSION.